TScan Therapeutics (TCRX) EBT Margin (2020 - 2026)
TScan Therapeutics' (TCRX) quarterly EBT Margin came in at 2919.14% in Q1 2026, down 121560.0% year-on-year from N/an in Q1 2025, and down 132.82% on a QoQ basis from 1253.84% in Q4 2025.
TScan Therapeutics (TCRX) EBT Margin (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has 7 years of EBT Margin data on file, last reported at 2919.14% in Q1 2026.
- On a quarterly basis, EBT Margin fell 121560.0% year-over-year to 2919.14% in Q1 2026; TTM through Mar 2026 was 1461.41%, a 182439.0% increase from a year earlier, with the FY2025 full-year figure at 2129.37%, up 300451.0% from the prior year.
- EBT Margin for Q1 2026 stood at 2919.14%, down from 1253.84% in the prior quarter.
- Over the last five years, EBT Margin for TCRX reached as high as 350.21% in Q4 2023 and fell as low as 7027.52% in Q4 2024.
- Historically, EBT Margin has averaged 1983.84% across 5 years, with a median of 1201.3% in 2025.
- Across the five-year window, EBT Margin sank 667730 bps in 2024 and soared 577368 bps in 2025, its largest moves.
- Year by year, EBT Margin stood at 631.57% in 2022, then soared by 45 bps to 350.21% in 2023, then slumped by 1907 bps to 7027.52% in 2024, then surged by 82 bps to 1253.84% in 2025, then tumbled by 133 bps to 2919.14% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 2919.14% in Q1 2026, 1253.84% in Q4 2025, and 1422.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | TScan Therapeutics | 100.59 Mn | -27.47 Mn | - | -2,919.14% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,919.14% |
| Dec 31, 2025 | -1,253.84% |
| Sep 30, 2025 | -1,422.14% |
| Jun 30, 2025 | -1,201.30% |
| Mar 31, 2025 | -1,703.55% |
| Dec 31, 2024 | -7,027.52% |
| Sep 30, 2024 | -2,849.09% |
| Jun 30, 2024 | -5,906.90% |
| Mar 31, 2024 | -5,325.44% |
| Dec 31, 2023 | -350.21% |
| Sep 30, 2023 | -591.64% |
| Jun 30, 2023 | -763.82% |
| Mar 31, 2023 | -389.02% |
| Dec 31, 2022 | -631.57% |
| Sep 30, 2022 | -483.05% |
| Jun 30, 2022 | -372.21% |
| Mar 31, 2022 | -534.79% |
| Dec 31, 2021 | -571.83% |
| Sep 30, 2021 | -1,048.55% |
| Jun 30, 2021 | -1,155.51% |